Wang Haiyan, Li Guimei, Yin Yongxiang, Wang Jianjun, Wang Hai, Wei Wei, Guo Qing, Ma Henghui, Shi Qunli, Zhou Xiaojun, Wang Jiandong
Department of Pathology, Jinling Hospital, Southern Medical University Nanjing 210002, China.
Department of Pathology, Jingdu Hospital Nanjng 210002, China.
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7881-9. eCollection 2014.
Epithelial ovarian cancer is the most common tumor of ovary. PTK7 plays an important role in tumors. Till now, there is no report about the role of PTK7 in ovarian epithelial neoplasms. This study aims to investigate the expression of PTK7 protein in epithelial ovarian tumors, and its relationship with clinical pathological characteristics. In this study, immunohistochemical staining was used to detect the expression of PTK7 protein in 14 samples of normal fallopian tube epithelium and 204 cases of epithelial ovarian tumor. The relationship between the expression of PTK7 and pathological indicators was statistically analyzed. Kaplan-Meier survival function was used to analyze the prognosis. The expression of PTK7 was found in 92.86% (13/14) of normal fallopian tube epithelium and 45.10% (92/204) of epithelial ovarian tumor tissues. The expression level of PTK7 was significantly decreased from the benign, the intermediate type, to malignant ovarian epithelial tumors (P < 0.001), and decreased from the normal control group to serous carcinomas (P < 0.001). The expression of PTK7 was significantly different in type I and type II epithelial ovarian carcinomas (P < 0.001). PTK7 protein expression was associated with clinical stages (P = 0.038) and metastases (P = 0.038) in ovarian borderline serous tumors. PTK7 protein expression was associated with clinical stages (P = 0.011), WHO grading (P = 0.004), and MDACC grading (P < 0.001) in ovarian serous carcinomas. The survival analysis showed that patients with negative expression of PTK7 protein had a poorer outcome than those with positive expression (P = 0.017). These results indicate that PTK7 protein may be a tumor suppressor and a potential prognostic marker in ovarian serous carcinomas.
上皮性卵巢癌是卵巢最常见的肿瘤。PTK7在肿瘤中发挥重要作用。到目前为止，尚无关于PTK7在卵巢上皮性肿瘤中作用的报道。本研究旨在探讨PTK7蛋白在上皮性卵巢肿瘤中的表达及其与临床病理特征的关系。在本研究中，采用免疫组织化学染色检测14例正常输卵管上皮样本和204例上皮性卵巢肿瘤中PTK7蛋白的表达。对PTK7表达与病理指标之间的关系进行统计学分析。采用Kaplan-Meier生存函数分析预后。结果发现，PTK7在92.86%（13/14）的正常输卵管上皮和45.10%（92/204）的上皮性卵巢肿瘤组织中表达。从良性、中间型到恶性卵巢上皮性肿瘤，PTK7的表达水平显著降低（P<0.001），从正常对照组到浆液性癌也降低（P<0.001）。PTK7在Ⅰ型和Ⅱ型上皮性卵巢癌中的表达有显著差异（P<0.001）。在卵巢交界性浆液性肿瘤中，PTK7蛋白表达与临床分期（P=0.038）和转移（P=0.038）相关。在卵巢浆液性癌中，PTK7蛋白表达与临床分期（P=0.011）、世界卫生组织分级（P=0.004）和MDACC分级（P<0.001）相关。生存分析表明，PTK7蛋白表达阴性的患者预后比阳性患者差（P=0.017）。这些结果表明，PTK7蛋白可能是卵巢浆液性癌中的一种肿瘤抑制因子和潜在的预后标志物。
